Chronic Hepatitis C virus infection in Swiss primary care practices: Low case loads-high barriers to treatment?

被引:4
作者
Overbeck, Kathrin [2 ]
Bruggmann, Philip [3 ]
Helbling, Beat [1 ]
机构
[1] Stadtspital Waid, Dept Gastroenterol & Hepatol, CH-8037 Zurich, Switzerland
[2] Univ Zurich Hosp, Dept Internal Med, Zurich, Switzerland
[3] ARUD Assoc Risk Reduct Drugs, Zurich, Switzerland
关键词
Hepatitis C; primary care physician; disease workup; patient monitoring; barriers to treatment; THERAPY; MANAGEMENT; PREDICTORS; PHYSICIANS; PATIENT; RATES;
D O I
10.3109/13814788.2010.545122
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: The primary care physician (PCP) diagnoses chronic Hepatitis C virus (HCV) infection in most patients. He serves as gatekeeper and plays a key role in counselling and treatment guidance. Objectives: To calculate the approximate HCV caseload per practice and characterize PCPs management of the disease; in particular, to determine antiviral treatment rates and reasons for PCPs for withholding treatment. The ultimate objective was to identify potentially modifiable barriers to treatment. Methods: A confidential self-administered questionnaire centred on the above-mentioned questions was distributed to 2371 Swiss primary care physicians. All respondents of the main questionnaire received an additional small questionnaire focussed on the initial disease workup. Descriptive statistics were used to describe questionnaire responses and PCP demographics. Results : The response rate was 53.1%. Of all participating PCPs (n = 1084), 86.2% reported having patients with chronic HCV, with an average number of 4 patients per practice; 18.6% (n = 142) of PCPs did not monitor their chronic HCV patients. Two-thirds (66.8%) of the sample chronic HCV patient population (n = 4626) never received antiviral therapy. The main reasons given by PCPs for withholding treatment were HCV-specialist advice, patient preference, normal liver enzymes and patient related factors like substance abuse or psychiatric co morbidity. Conclusions: Most PCPs follow patients with chronic hepatitis C, but practice caseloads are low, which may account for insecurity in managing this complex disease.
引用
收藏
页码:103 / 108
页数:6
相关论文
共 50 条
  • [21] Integrated Care Increases Treatment and Improves Outcomes of Patients With Chronic Hepatitis C Virus Infection and Psychiatric Illness or Substance Abuse
    Ho, Samuel B.
    Braeu, Norbert
    Cheung, Ramsey
    Liu, Lin
    Sanchez, Courtney
    Sklar, Marisa
    Phelps, Tyler E.
    Marcus, Sonja G.
    Wasil, Michelene M.
    Tisi, Amelia
    Huynh, Lia
    Robinson, Shannon K.
    Gifford, Allen L.
    Asch, Steven M.
    Groesslk, Erik J.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (11) : 2005 - +
  • [22] Virus C genotype predisposes to primary hypothyroidism during interferon-α treatment for chronic hepatitis C
    Postal Pavan, Maria Helena
    Pavin, Elizabeth Joao
    Goncales, Fernando Lopes, Jr.
    Zantut Wittmann, Denise Engelbrecht
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2011, 15 (05) : 449 - 456
  • [23] Outcomes of Low Barrier Hepatitis C Treatment in High Risk Populations From Primary Care
    Austin, Scarlett
    Seemiller, Kristi
    Nolton, Brittany
    Hobart, Emily
    Ling, Bruce
    Ghobrial, Jonathan
    Robertson, Thomas
    JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES, 2024, 14 (06):
  • [24] Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons
    Mocroft, Amanda
    Ryom, Lene
    Oprea, Cristiana
    Li, Qiuju
    Rauch, Andri
    Boesecke, Christoph
    Uzdaviniene, Vilma
    Sedlacek, Dalibor
    Llibre, Josep M.
    Lacombe, Karine
    Nielsen, Lars N.
    Florence, Eric
    Aho, Inka
    Chkhartishvili, Nikoloz
    Szlavik, Janos
    Dragovic, Gordana
    Leen, Clifford
    Sambatakou, Helen
    Staub, Therese
    Laguno, Montse
    Elinav, Hila
    Peters, Lars
    AIDS, 2020, 34 (10) : 1485 - 1495
  • [25] Direct antivirals for the treatment of chronic hepatitis C virus infection. Experience in 106 patients
    Ignacio Vargas, Jose
    Pablo Arab, Juan
    Monrroy, Hugo
    Labbe, Pilar
    Sarmiento, Valeska
    Fuster, Felipe
    Barrera, Francisco
    Benitez, Carlos
    Arrese, Marco
    Fuster, Francisco
    Soza, Alejandro
    REVISTA MEDICA DE CHILE, 2017, 145 (10) : 1235 - 1242
  • [26] Cost-Effectiveness of Access Expansion to Treatment of Hepatitis C Virus Infection Through Primary Care Providers
    Rattay, Thilo
    Dumont, Ian P.
    Heinzow, Hauke S.
    Hutton, David W.
    GASTROENTEROLOGY, 2017, 153 (06) : 1531 - +
  • [27] Current Approaches to the Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease
    Oruc, Aysegul
    Ersoy, Alparslan
    TURKISH NEPHROLOGY DIALYSIS AND TRANSPLANTATION JOURNAL, 2016, 25 : 31 - 40
  • [28] Interferon-alpha treatment of chronic hepatitis C virus infection in children
    Jonas, MM
    Ott, MJ
    Nelson, SP
    Badizadegan, K
    Perez-Atayde, AR
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1998, 17 (03) : 241 - 246
  • [29] Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs
    Treloar, Carla
    Hull, Peter
    Dore, Gregory J.
    Grebely, Jason
    DRUG AND ALCOHOL REVIEW, 2012, 31 (07) : 918 - 924
  • [30] Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection
    Cheng, Elaine Y.
    Saab, Sammy
    Holt, Curtis D.
    Busuttil, Ronald W.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (18) : 2835 - 2848